{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:04:57Z","timestamp":1789643097153,"version":"4.0.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaad.2026.06.021","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:27:02Z","timestamp":1780936022000},"page":"1071-1082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-1\u2013targeted therapy in dermatologic conditions"],"prefix":"10.1016","volume":"95","author":[{"given":"Kerem","family":"Balan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Elston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jaad.2026.06.021_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41423-025-01358-8","article-title":"IL-1 family cytokines in inflammation and immunity","volume":"22","author":"Garlanda","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.021_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and related cytokines in the regulation of inflammation and immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.021_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jaad.2017.11.064","article-title":"Neutrophilic dermatoses: pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behcet disease","volume":"79","author":"Nelson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.021_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652846","article-title":"IL-1 family antagonists in mouse and human skin inflammation","volume":"12","author":"Martin","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/med.21406","article-title":"The role of Interleukin-1 in inflammatory and malignant human skin diseases and the rationale for targeting Interleukin-1 alpha","volume":"37","author":"Bou-Dargham","year":"2017","journal-title":"Med Res Rev"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.021_bib6","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.3928\/19382359-20220115-01","article-title":"The role of anti-IL-1 medications in autoinflammatory disease","volume":"51","author":"Semo-Oz","year":"2022","journal-title":"Pediatr Ann"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.021_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jid.2023.11.004","article-title":"Emerging role of the IL-36\/IL-36R axis in multiple inflammatory skin diseases","volume":"144","author":"Ahmad","year":"2024","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.021_bib8","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/jcm13041026","article-title":"Analysis of anakinra therapy for the deficiency of Interleukin-1 receptor antagonist through clinical evidence","volume":"13","author":"Pillai","year":"2024","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.jaad.2026.06.021_bib9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.autrev.2014.08.031","article-title":"Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study","volume":"13","author":"Neel","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13075-019-2021-9","article-title":"Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts","volume":"21","author":"Colafrancesco","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2026.06.021_bib13","article-title":"Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review","volume":"14","author":"Sanz-Cabanillas","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.021_bib14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jaci.2016.07.041","article-title":"Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study","volume":"139","author":"Krause","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.021_bib15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/cpt.1302","article-title":"Dosage considerations for canakinumab in children with periodic fever syndromes","volume":"106","author":"Zhuang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jaad.2026.06.021_bib17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1398-9995.2012.02843.x","article-title":"Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study","volume":"67","author":"Krause","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2026.06.021_bib18","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.2147\/JMDH.S500838","article-title":"Comprehensive clinical analysis of rilonacept in the treatment of cryopyrin-associated periodic syndromes: a systematic review","volume":"18","author":"Zhang","year":"2025","journal-title":"J Multidiscip Healthc"},{"issue":"9","key":"10.1016\/j.jaad.2026.06.021_bib19","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jcph.372","article-title":"Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis","volume":"55","author":"Autmizguine","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2026.06.021_bib22","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3389\/fimmu.2019.02448","article-title":"Dermatologic and dermatopathologic features of monogenic autoinflammatory diseases","volume":"10","author":"Figueras-Nart","year":"2019","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.jaad.2026.06.021_bib23","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jaad.2026.06.021_bib24","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jaad.2026.06.021_bib25","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","article-title":"Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study","volume":"34","author":"Hoffman","year":"2012","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.021_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/ar3535","article-title":"Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study","volume":"13","author":"Kone-Paut","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.25057","article-title":"Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome","volume":"62","author":"Neven","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2026.06.021_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.823847","article-title":"Anakinra in paediatric rheumatology and periodic fever clinics: is the higher dose safe?","volume":"10","author":"Fingerhutova","year":"2022","journal-title":"Front Pediatr"},{"issue":"7","key":"10.1016\/j.jaad.2026.06.021_bib29","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13075-024-03316-7","article-title":"Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009-2022: an interim analysis using the French JIR cohort database","volume":"26","author":"Kone-Paut","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12969-019-0338-1","article-title":"Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents","volume":"17","author":"Hospach","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.021_bib32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.semarthrit.2020.05.002","article-title":"Efficacy and safety of canakinumab treatment in Schnitzler syndrome: a systematic literature review","volume":"50","author":"Betrains","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.jaad.2026.06.021_bib33","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamadermatol.2017.2392","article-title":"Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases","volume":"153","author":"Houriet","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.06.021_bib34","first-page":"36","article-title":"Non-response to Interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa","volume":"10","author":"Sun","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2026.06.021_bib35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jid.2025.07.032","article-title":"A phase 2, randomized, placebo-controlled study of bermekimab in moderate-to-severe hidradenitis suppurativa","volume":"146","author":"Forman","year":"2026","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7326\/L15-5107","article-title":"Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report","volume":"163","author":"Acquitter","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jaad.2026.06.021_bib38","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1097\/MS9.0000000000002533","article-title":"A complex case of PASH syndrome: pyoderma gangrenosum, acne, suppurative hidradenitis, and Crohn's disease in a 36-year-old smoker","volume":"86","author":"Abdul Rahman","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.021_bib39","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2025.2495834","article-title":"Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review","volume":"36","author":"Yang","year":"2025","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-153-1-201007060-00030","article-title":"Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations","volume":"153","author":"Viguier","year":"2010","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.021_bib43","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjd.14685","article-title":"Successful response in a case of severe pustular psoriasis after interleukin-1beta inhibition","volume":"176","author":"Skendros","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.021_bib44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjd.20653","article-title":"Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)","volume":"186","author":"Cro","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.021_bib45","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.jaad.2022.07.065","article-title":"Anakinra for refractory pustular psoriasis: a phase II, open-label, dose-escalation trial","volume":"87","author":"Naik","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.021_bib46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/biom14060646","article-title":"Schnitzler syndrome: insights into its pathogenesis, clinical manifestations, and current management","volume":"14","author":"Braud","year":"2024","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.jaad.2026.06.021_bib47","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","article-title":"Successful treatment of severe hidradenitis suppurativa with anakinra","volume":"149","author":"Zarchi","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.021_bib48","first-page":"772","article-title":"Failure of anakinra in a case of severe hidradenitis suppurativa","volume":"15","author":"Russo","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2026.06.021_bib50","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/ced.14809","article-title":"Anakinra for recalcitrant pyoderma gangrenosum","volume":"46","author":"O'Connor","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2026.06.021_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdcr.2021.07.019","article-title":"A case of extracutaneous pyoderma gangrenosum in a patient with persistent cutaneous and systemic symptoms: implications for differential diagnosis and treatment","volume":"15","author":"Santa Lucia","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.021_bib52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000326112","article-title":"Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet's syndrome","volume":"222","author":"Kluger","year":"2011","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.021_bib53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.semarthrit.2018.04.003","article-title":"Biologics in SAPHO syndrome: a systematic review","volume":"48","author":"Daoussis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.jaad.2026.06.021_bib54","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamadermatol.2024.1657","article-title":"Skin manifestations of VEXAS syndrome and associated genotypes","volume":"160","author":"Tan","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.021_bib55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2340\/00015555-2924","article-title":"Inflammasome activation characterizes lesional skin of Folliculitis decalvans","volume":"98","author":"Eyraud","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.021_bib56","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000443648","article-title":"PASS syndrome: an IL-1-driven autoinflammatory disease","volume":"232","author":"Leuenberger","year":"2016","journal-title":"Dermatology"},{"issue":"7","key":"10.1016\/j.jaad.2026.06.021_bib57","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant Interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2026.06.021_bib58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.43384","article-title":"Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome: an international multicenter study","volume":"78","author":"Eviatar","year":"2026","journal-title":"Arthritis Rheumatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226028483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226028483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:57:56Z","timestamp":1789642676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226028483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0190962226028483"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.021","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-1\u2013targeted therapy in dermatologic conditions","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}